<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> stem cells are implicated in <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e>, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and recurrence, although the exact mechanisms remain poorly understood </plain></SENT>
<SENT sid="1" pm="."><plain>Here we show that the expression of cellular prion protein (PrPc, PRNP) is positively correlated with an increased risk of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>PrPc defines a subpopulation of CD44-positive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells that contributes to metastatic capacity </plain></SENT>
<SENT sid="3" pm="."><plain>PrPc+CD44+ <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> stem cells displayed high liver metastatic capability, unlike PrPc-CD44+ stem cells, that was inhibited by RNAi-mediated attenuation of PrPc </plain></SENT>
<SENT sid="4" pm="."><plain>Notably, administration of PrPc monoclonal antibodies significantly inhibited tumorigenicity and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> stem cells in mouse models of orthotopic <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>PrPc promoted epithelial to mesenchymal transition (EMT) via the ERK2 (MAPK1) pathway, thereby conferring high metastatic capacity </plain></SENT>
<SENT sid="6" pm="."><plain>Our findings reveal the function of PrPc in regulating EMT in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells, and they identify PrPc as candidate therapeutic target in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
</text></document>